Refractory marginal zone lymphoma uncovers activated phosphoinositide 3-kinase delta syndrome type 1 (APDS1)
Activated PI3K delta syndrome is a rare primary combined immunodeficiency that can present with lymphoma. Genetic testing of patients with atypical lymphoma may reveal an underlying immunodeficiency and improve clinical outcomes.
Authors
- Holly Miller
- Charlotte Cunningham‐Rundles (ORCID: https://orcid.org/0000-0003-0725-0320)
- Alex Wonnaparhown
- Catherine Freeman (ORCID: https://orcid.org/0000-0003-0312-0609)
- Allison Rosenthal (ORCID: https://orcid.org/0000-0002-8915-3163)
- Jacqueline D. Squire (ORCID: https://orcid.org/0000-0002-2600-1306)
- Talal Hilal (ORCID: https://orcid.org/0000-0001-8249-4128)
- Matthew Farley
Institutions
- Jacksonville College (US)
- Atlanta Allergy and Asthma Clinic (US)
- Center for Cancer and Blood Disorders (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1016/j.jacig.2025.100503
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Mayo Clinic
- Division of Cancer Prevention, National Cancer Institute
- Paula and Rodger Riney Foundation
- National Institutes of Health
- National Cancer Institute